Hairuo Wen1, Zhe Qu1, Yujing Yan1,2, Chengfei Pu3, Chao Wang1, Hua Jiang1, Tiantian Hou1, Yan Huo1. 1. Key Laboratory of Beijing for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China. 2. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. 3. Innovative Cellular Therapeutics Co., Ltd., Shanghai 201203, China.
Abstract
BACKGROUND: With the increase of chimeric antigen receptor-modified T (CAR-T) cell therapy, serious complications initiated by CAR-T cells have garnered wide attention. We have previously developed a 4-1BB/CD3-ζ-costimulated CAR-T cells against CD19 (CART19) for adult acute lymphoblastic leukemia (ALL). In this study, a preclinical safety assessment of CART19 was performed on NSG mice, to evaluate the preclinical toxicity along with its efficacy and tissue distribution. METHODS: A total of 120 NSG mice were used for a combined pharmacodynamics and toxicity study for 56 days. Ninety-six mice of which were single dosed with Raji-Luc (5×105 per animal, i.p.) and different concentrations of CART19 (0.2×107, 0.6×107 and 1.8×107 per animal, i.v.), while the rest were assigned to the Untreated group. Optical intensity of Raji-Luc in mice, clinical symptoms, body mass, hematological analysis, humanized cytokine, lymphocyte subset counting, necropsy and histopathological examinations were performed. In addition, a single dose of 0.6×107 CART19 was intravenously administered to 48 NSG mice, and the distribution of CART19 in different tissues was analyzed using quantitative PCR. RESULTS: CART19 is widely distributed in organs well-perfused with blood, including the lungs, blood, bone marrow, liver and spleen. Significant proliferation of CART19 was also found in the blood by through recognition using humanized CD3+ for T lymphocytes. The survival rate and leukemia related clinical symptoms in mice administered CART19 were markedly ameliorated, and the proliferation of Raji cells in mice was effectively inhibited. However, CART19 had no obvious effects on either the mean body mass or the blood cell counts, and no cytokine release syndrome and graft versus host disease were observed. CONCLUSIONS: NSG mice given CART19 treatment demonstrated a longer survival period without significant immunotoxicity, suggesting encouraging clinical prospects for CART19 in patients with R/R ALL. Our study shed light on evaluation and supervision strategies for CAR-T products for the treatment of hematological diseases or leukemia. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: With the increase of chimeric antigen receptor-modified T (CAR-T) cell therapy, serious complications initiated by CAR-T cells have garnered wide attention. We have previously developed a 4-1BB/CD3-ζ-costimulated CAR-T cells against CD19 (CART19) for adult acute lymphoblastic leukemia (ALL). In this study, a preclinical safety assessment of CART19 was performed on NSG mice, to evaluate the preclinical toxicity along with its efficacy and tissue distribution. METHODS: A total of 120 NSG mice were used for a combined pharmacodynamics and toxicity study for 56 days. Ninety-six mice of which were single dosed with Raji-Luc (5×105 per animal, i.p.) and different concentrations of CART19 (0.2×107, 0.6×107 and 1.8×107 per animal, i.v.), while the rest were assigned to the Untreated group. Optical intensity of Raji-Luc in mice, clinical symptoms, body mass, hematological analysis, humanized cytokine, lymphocyte subset counting, necropsy and histopathological examinations were performed. In addition, a single dose of 0.6×107 CART19 was intravenously administered to 48 NSG mice, and the distribution of CART19 in different tissues was analyzed using quantitative PCR. RESULTS: CART19 is widely distributed in organs well-perfused with blood, including the lungs, blood, bone marrow, liver and spleen. Significant proliferation of CART19 was also found in the blood by through recognition using humanized CD3+ for T lymphocytes. The survival rate and leukemia related clinical symptoms in mice administered CART19 were markedly ameliorated, and the proliferation of Raji cells in mice was effectively inhibited. However, CART19 had no obvious effects on either the mean body mass or the blood cell counts, and no cytokine release syndrome and graft versus host disease were observed. CONCLUSIONS: NSG mice given CART19 treatment demonstrated a longer survival period without significant immunotoxicity, suggesting encouraging clinical prospects for CART19 in patients with R/R ALL. Our study shed light on evaluation and supervision strategies for CAR-T products for the treatment of hematological diseases or leukemia. 2019 Annals of Translational Medicine. All rights reserved.
Authors: Christopher A Pennell; Jessie L Barnum; Cameron S McDonald-Hyman; Angela Panoskaltsis-Mortari; Megan J Riddle; Zhengming Xiong; Michael Loschi; Govindarajan Thangavelu; Heather M Campbell; Meghan D Storlie; Yosef Refaeli; Scott N Furlan; Michael C Jensen; Leslie S Kean; Jeffrey S Miller; Jakub Tolar; Mark J Osborn; Bruce R Blazar Journal: Mol Ther Date: 2018-04-07 Impact factor: 11.454
Authors: Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall Journal: Lancet Date: 2014-10-13 Impact factor: 79.321
Authors: Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Sarah K Tasian; Saad S Kenderian; Feng Shen; Marco Ruella; Olga Shestova; Miroslaw Kozlowski; Yong Li; April Schrank-Hacker; Jennifer J D Morrissette; Martin Carroll; Carl H June; Stephan A Grupp; Saar Gill Journal: Blood Date: 2017-02-28 Impact factor: 22.113
Authors: D A Rizzieri; P Dev; G D Long; C Gasparetto; K M Sullivan; Ml Horwitz; J Chute; N J Chao Journal: Bone Marrow Transplant Date: 2008-10-13 Impact factor: 5.483
Authors: H J Pegram; T J Purdon; D G van Leeuwen; K J Curran; S A Giralt; J N Barker; R J Brentjens Journal: Leukemia Date: 2014-07-09 Impact factor: 11.528
Authors: Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz Journal: Annu Rev Pathol Date: 2016-12-05 Impact factor: 23.472
Authors: Eleanor J Cheadle; Victoria Sheard; Dominic G Rothwell; John S Bridgeman; Garry Ashton; Vivien Hanson; A Wasat Mansoor; Robert E Hawkins; David E Gilham Journal: J Immunol Date: 2014-03-12 Impact factor: 5.422
Authors: Elke Anklam; Martin Iain Bahl; Robert Ball; Richard D Beger; Jonathan Cohen; Suzanne Fitzpatrick; Philippe Girard; Blanka Halamoda-Kenzaoui; Denise Hinton; Akihiko Hirose; Arnd Hoeveler; Masamitsu Honma; Marta Hugas; Seichi Ishida; George En Kass; Hajime Kojima; Ira Krefting; Serguei Liachenko; Yan Liu; Shane Masters; Uwe Marx; Timothy McCarthy; Tim Mercer; Anil Patri; Carmen Pelaez; Munir Pirmohamed; Stefan Platz; Alexandre Js Ribeiro; Joseph V Rodricks; Ivan Rusyn; Reza M Salek; Reinhilde Schoonjans; Primal Silva; Clive N Svendsen; Susan Sumner; Kyung Sung; Danilo Tagle; Li Tong; Weida Tong; Janny van den Eijnden-van-Raaij; Neil Vary; Tao Wang; John Waterton; May Wang; Hairuo Wen; David Wishart; Yinyin Yuan; William Slikker Journal: Exp Biol Med (Maywood) Date: 2021-11-16
Authors: Daria S Chulpanova; Kristina V Kitaeva; Catrin S Rutland; Albert A Rizvanov; Valeriya V Solovyeva Journal: Int J Mol Sci Date: 2020-06-09 Impact factor: 5.923
Authors: Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Kristen A Froehlich; Anton Jansson; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno Journal: Nat Biotechnol Date: 2022-03-24 Impact factor: 68.164